See the DrugPatentWatch profile for Tivicay
ViiV Healthcare manufactures Tivicay [1]. ViiV Healthcare is majority-owned by GlaxoSmithKline (GSK), with Pfizer and Shionogi Limited as minority shareholders [1].
What is Tivicay used for?
Tivicay is a prescription medicine used to treat human immunodeficiency virus (HIV) infection in adults and children at least 4 weeks old and weighing at least 4 pounds [2]. It is typically used in combination with other HIV medicines [2].
How does Tivicay work?
Tivicay belongs to a class of drugs called HIV integrase strand transfer inhibitors (INSTIs) [2]. It works by blocking the action of HIV integrase, an enzyme that HIV needs to multiply [2]. By inhibiting this enzyme, Tivicay helps reduce the amount of HIV in the body [2].
When does Tivicay's patent expire?
Information on the specific patent expiry dates for Tivicay is available on DrugPatentWatch.com [3].
What are the alternatives to Tivicay?
Other HIV integrase strand transfer inhibitors include dolutegravir (the active ingredient in Tivicay), bictegravir, raltegravir, and elvitegravir [4]. Treatment for HIV is individualized, and a healthcare provider will determine the most appropriate combination of medications based on a patient's specific needs and medical history [2].